ALKS
Alkermes plc · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 121 | +1 | 123.13M | $6.45B | +12 | −10 |
| Q1 2026 | 122 | -3 | 122.08M | $4.29B | +3 | −7 |
| Q4 2025 | 124 | +2 | 142.93M | $4.00B | +3 | — |
| Q3 2025 | 20 | -1 | 95.12M | $2.85B | — | −2 |
| Q2 2025 | 19 | +2 | 84.64M | $2.42B | +2 | — |
| Q1 2025 | 14 | 0 | 39.73M | $1.31B | — | — |
| Q4 2024 | 14 | 0 | 45.20M | $1.30B | — | — |
| Q3 2024 | 13 | +2 | 43.42M | $1.22B | +2 | — |
| Q2 2024 | 11 | — | 42.07M | $1.01B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 14.35M | — | $345.95M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 14.35M | — | $345.95M | 0.1% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 14.35M | — | $345.95M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 14.35M | — | $345.95M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 14.35M | — | $345.95M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 14.35M | — | $345.95M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 14.35M | — | $345.95M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 11.01M | — | $265.40M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 11.01M | — | $265.40M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 5.48M | — | $132.16M | 0.2% | n/c | 1 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passive) | 3.93M | — | $94.83M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Geode Capital Management ✦ (passive) | 3.93M | — | $94.83M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | PRIMECAP Management ✦ | 3.39M | — | $81.60M | 0.1% | n/c | 1 | SEC ↗ |
| 14 | Norges Bank ✦ (passive) | 2.13M | — | $51.31M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 803.50K | — | $19.36M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 803.50K | — | $19.36M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 803.50K | — | $19.36M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 323.14K | — | $7.79M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | D. E. Shaw & Co. ✦ | 323.14K | — | $7.79M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Citadel Advisors ✦ | 322.21K | — | $7.77M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Fisher Asset Management ✦ | 242.64K | — | $5.85M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | Two Sigma Investments ✦ | 78.73K | — | $1.90M | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 384 holders, 171.47M shares, $5.79B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 6.91K sh · $339,967
Officer · 664 sh · $32,969
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology